A transition from the use of HFA 134a and HFA 227 as propellants in metered dose inhalers (MDIs) to lower global warming potential (LGWP) propellants is in the early stages
Learn more about these LGWP propellants:
Recent news about LGWP propellants:
-
Chiesi announces European regulatory submissions for LGWP formulations of BDP/FF/GB and BDP/FF MDIs
-
HFO 1234ze formulation of AstraZeneca’s Breztri Aerosphere budesonide / glycopyrronium / formoterol MDI approved in Australia
-
MHRA approves HFA 152a formulation of Chiesi’s Clenil Modulite beclametasone MDI
-
Orbia announces submission of DMF for Zephex 152a LGWP MDI propellant
-
Bespak to increase MDI capacity at its Holmes Chapel site to support Chiesi LGWP transition
Resources for the LGWP transition
Videos
Learn more about the transition:
IPAC-RS Workshop on the transition
View IPAC-RS’s October 11, 2023 Workshop on the Transition to Low Global Warming Potential Propellants for Metered Dose Inhalers
Page sponsored by Bespak
